Providence Medical Research Center :: COSTAR CObalt chromium STent with Antiproliferative for Restenosis II Trial (The COSTAR II Trial)

You Are Here: Home

Areas of Research

Cardiology

Study Keyword Search

COSTAR CObalt chromium STent with Antiproliferative for Restenosis II Trial (The COSTAR II Trial)

Primary Investigator:
Angelo Ferraro MD

Description:

This study examines the safety and effectiveness of two different drug-eluting stents (CoStar^(R)and TAXUS^TM) in patients with symptomatic heart disease. Participants will have blockage(s) in one, two or three of their heart or coronary arteries as determined by angiography. They will be randomized to receive either the TAXUS stent (coated with paclitaxel) or the CoStar stent (paclitaxel loaded into reservoirs located within the stent struts). Participants in the trial will be followed for a period of 5 years.

Eligibility:

Age 18 years or older
Have stable or unstable angina
Meet angiographic criteria as determined by a heart or coronary angiogram
Other eligibility criteria may apply. Please contact study coordinator.

Exclusions:

Unable to take aspirin or Plavix
Other exclusion criteria may apply. Please contact study coordinator.

Study Timeline:
Closed to enrollment

Study Contact:
Debbie, CCRC Debbie.Westover@providence.org

Study Sponsor:
Conor Medsystems

Keywords :